ArticleClinical and experimental pediatrics2026
High-Risk CCL14 lineage drives severe Mycoplasma pneumoniae pneumonia in children: a study in central China.
Article in Clinical and experimental pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background: The post-coronavirus disease 2019 (COVID-19) pandemic resurgence of Mycoplasma pneumoniae (MP) infections, particularly in China, underscores the need to understand the drivers of disease severity. Purpose: This study aimed to evaluate the association between predominantly circulating MP strains and disease severity in Henan Province, central China. Methods: We integrated the clinical data of 3,060 pediatric patients and analyzed the epidemiological characteristics of MP pneumonia (MPP) in the Henan region in 2020-2024. Bronchoalveolar lavage fluid collected from 137 patients was analyzed using multilocus sequence typing and multilocus variable number tandem-repeat analysis to investigate the correlation between genotype and clinical outcome. Results: A significant post-COVID MPP outbreak was predicted in 2023. Genotyping revealed the cocirculation of 2 major genotypes: the prevalent ST3 (57.7%, severe ratio [31.6%]) and the less common but highly virulent ST14 (26.3%, severe ratio [72.2%]). Phylogenetic clustering confirmed ST14/3-5-6-2 as part of a broader hypervirulent lineage, common cluster label 14 (CCL14), which was significantly associated with disease severity (χ2=19.39; P<0.001). Patients infected with CCL14 strains exhibited a distinct hyperinflammatory profile marked by elevated D-dimer levels, complement C4 levels, and platelet count. The mutation ratio of macrolide resistance sites in the MP strains from Henan Province was approximately 75%. Conclusion: Our findings identified the CCL14 lineage as a key driver of disease severity in macrolide-resistant pediatric MPP in Henan Province, China. This under scores the importance of integrating molecular surveillance with clinical monitoring to mitigate disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.